DiscGenics granted 9 new patents for DiscoGenic Cell technology


DiscGenics has been granted 9 new patents, expanding its intellectual property portfolio within both the US and globally to 24 issued patents. The new patents include two in the US and seven in European markets.

The patent portfolio provides coverage on its proprietary culture process and novel Discogenic Cell technology that is the therapeutic agent within its first product, Injectable Discogenic Cell Therapy (IDCT). The company is currently in the process of completing its preclinical development and looks forward to initiating initial human clinical trial during 2017 pending regulatory approvals.